newsfilter
← Earnings
Earnings Releases·

Neumora Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss narrowed to $34.4 million (down from $56.8 million YoY) as total operating expenses fell 42% to $33.4 million, driven by reduced clinical trial and personnel costs.
  • Cash reserves declined to $85.7 million from $182.5 million at year-end 2025, with management acknowledging a need for substantial additional funding and actively evaluating options to reach next value inflection points.
  • Key pipeline milestones include the FDA IND submission for NMRA-215 (obesity/cardiometabolic) and favorable Phase 1b safety data for NMRA-511, which is now Phase 2 enabled.
  • The company provided no updated financial runway guidance, citing uncertainty regarding the availability of future funding on favorable terms.
Company
NEUMORA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology